Dark

Check out our Dark Pool Levels

NANO
Nordic Nanovector ASA
stock NASDAQ

Inactive

Oct 25, 2019

35.33USD-0.814%(-0.29)1,166,831

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 26, 2022

04:15PM EST NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 Business Wire

Jan 11, 2022

04:15PM EST Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital Business Wire

Jan 5, 2022

04:15PM EST NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer Business Wire

Jan 4, 2022

04:15PM EST Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022 Business Wire

Dec 8, 2021

04:15PM EST Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital Business Wire

Nov 17, 2021

04:15PM EST NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference Business Wire

Nov 9, 2021

04:15PM EST NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination Business Wire

Nov 8, 2021

04:15PM EST Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital Business Wire

Nov 3, 2021

04:15PM EDT NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference Business Wire

Oct 24, 2021

05:02PM EDT NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy Business Wire

Oct 20, 2021

04:15PM EDT NANOBIOTIX Provides Third Quarter Operational and Financial Update Business Wire

Oct 8, 2021

04:15PM EDT Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital Business Wire

Oct 6, 2021

04:15PM EDT NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology Business Wire

Oct 4, 2021

09:04AM EDT Nano One Materials Corp. (TSX: NANO; OTC-Nasdaq Intl Designation: NNOMF; Frankfurt: LBMB) (Nano One) and Euro Manganese Inc. (TSX-V and ASX: EMN; OTCQX: EUMNF; Frankfurt: E06) (Euro Manganese) GlobeNewswire Inc

Sep 28, 2021

04:15PM EDT NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May "Reprogram" the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect Business Wire

Sep 9, 2021

04:15PM EDT Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital as of August 31, 2021 Business Wire

Sep 8, 2021

04:15PM EDT NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021 Business Wire

Sep 7, 2021

04:15PM EDT Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Business Wire

Jun 10, 2021

11:01AM EDT Nano One Materials Virtually Opens The Market PR Newswire

Apr 12, 2021

12:00PM EDT Nanobiotix Combined Shareholders Meeting to Be Held April 28, 2021 Business Wire

Apr 7, 2021

06:27PM EDT NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F Business Wire

Mar 17, 2021

05:15PM EDT NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress Business Wire

Mar 4, 2021

05:59PM EST NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration Business Wire

Mar 3, 2021

04:15PM EST NANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference Business Wire

Jan 15, 2021

08:17AM EST Nanobiotix Announces Positive First Results For Novel NBTXR3 In Rectal Cancer Study At ASCO-GI 2021 RTTNews

Jan 8, 2021

08:17AM EST Nanobiotix Announces Development Milestones For 2021 After Successful Nasdaq IPO RTTNews

08:00AM EST Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Business Wire

Dec 18, 2020

04:00PM EST Nanobiotix Announces Closing of Underwriters' Option to Purchase Additional ADSs Business Wire

Dec 15, 2020

05:00PM EST NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million Business Wire

Dec 11, 2020

02:27AM EST NANOBIOTIX Prices IPO Of 7.30 Mln Shares At $13.50/ADS RTTNews

02:22AM EST NANOBIOTIX Announces Pricing of Global Offering and Approval to List on NASDAQ Global Select Market Business Wire

Dec 9, 2020

07:59PM EST NANOBIOTIX Expects To Price IPO Of 6.50 Mln Shares To Be Between $13.50 And $14.50/shr RTTNews

07:40PM EST NANOBIOTIX Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Range Business Wire

Dec 7, 2020

07:24AM EST Nanobiotix Announces the Start of the Roadshow for Its Proposed Global Offering and Proposed Nasdaq Listing Business Wire

Dec 1, 2020

01:43AM EST Nordic Nanovector completes patient enrolment into Phase 1 trial of PR Newswire

Nov 30, 2020

02:21AM EST Nordic Nanovector announces change of its Oslo Bors ticker symbol to 'NANOV' PR Newswire

Nov 20, 2020

01:22PM EST NANOBIOTIX Files Registration Statement for Proposed Initial Public Offering in the United States Business Wire

Nov 19, 2020

01:43AM EST Nordic Nanovector ASA: Results for the Third Quarter 2020 PR Newswire

01:42AM EST lymphoma patients in Archer-1 Phase 1b Betalutin(r)/rituximab combination trial PR Newswire

Nov 16, 2020

06:45AM EST Nordic Nanovector to Present at Upcoming Jefferies Virtual London Healthcare PR Newswire

02:23AM EST Nordic Nanovector ASA: Invitation to Q3 2020 Results Presentation and Webcast PR Newswire

Nov 12, 2020

03:08AM EST NANOBOTIX Announces Positive New In Vivo Pre-clinical Data From Two Studies At The Society For SITC Meeting RTTNews

02:00AM EST NANOBIOTIX Announces Positive New Pre-clinical Data Suggesting Radioenhancer NBTXR3 Could Have a Significant Impact in Immunotherapy Business Wire

Oct 23, 2020

12:00PM EDT Nanobiotix Announces Third Quarter 2020 Revenue Business Wire

Oct 21, 2020

11:59AM EDT Nordic Nanovector ASA: Cancellation of Repair Offering PR Newswire

05:49AM EDT Nordic Nanovector ASA: Extraordinary general meeting held PR Newswire

Oct 20, 2020

02:00AM EDT NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting Business Wire

Oct 19, 2020

09:33AM EDT Nordic Nanovector ASA - Streaming details for EGM PR Newswire

Oct 13, 2020

02:12AM EDT NANOBIOTIX Announces First Patient Injected With NBTXR3 In Pancreatic Cancer RTTNews

02:00AM EDT NANOBIOTIX Announces First Patient Injected with NBTXR3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials From U.S. FDA Business Wire

Oct 8, 2020

02:26AM EDT Nordic Nanovector : Betalutin Reverses Tumour Resistance To Rituximab In NHL Disease Models RTTNews

02:23AM EDT Betalutin(r) reverses tumour resistance to rituximab in NHL disease models PR Newswire

Sep 4, 2020

12:00PM EDT NANOBIOTIX Announces Half-year Financial Statements as at June 30, 2020 Business Wire

Sep 3, 2020

02:13AM EDT Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published PR Newswire

Sep 1, 2020

10:32AM EDT Nordic Nanovector to Present at Upcoming Pareto Securities 11 th Healthcare PR Newswire

Aug 27, 2020

01:27AM EDT Nordic Nanovector ASA: Results for the Second Quarter and First Half 2020 PR Newswire

Aug 21, 2020

11:17AM EDT Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results PR Newswire

Aug 10, 2020

01:28AM EDT Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer PR Newswire

Aug 6, 2020

03:04AM EDT Nordic Nanovector Says Independent Review Committee Recommends To Focus On One Dosage Arm For PARADIGME Phase 2b Trial RTTNews

01:13AM EDT dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL PR Newswire

Jul 30, 2020

02:23AM EDT Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37 PR Newswire

Jul 17, 2020

12:20PM EDT Nanobiotix Announces Revenue for Second Quarter 2020 and First Half Year 2020 Business Wire

Share